Shares of NeuroMetrix (NSDQ:NURO) are soaring this morning on news of a U.S. regulatory win for its Sensus pain management system.
The FDA granted 510(k) clearance to the system but has yet to formally announce the decision, according to the watchdog agency’s website.
NURO shares surged as much as 22% this morning on the news and were up 10.8% to 72¢ as of about 10:20 a.m.
Sign up to get our free newsletters delivered straight to your inbox
The Sensus device is a transcutaneous nerve stimulator designed to relieve the symptoms of diabetic neuropathy by reducing the transmission of pain signals to the brain, according to the NeuroMetrix website.
It was a quick turnaround for the FDA this time around; NeuroMetrix filed its 510(k) application for the system in April.